Document:

Second Loan Modification Agreement

 Exhibit 10.22 
 EXECUTION VERSION 
 SECOND LOAN MODIFICATION AGREEMENT 

This Second Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of July 19, 2011,
by and among (i) MIDCAP FUNDING V, LLC, a Delaware limited liability company, as assignee of MIDCAP FUNDING III, LLC (“MidCap”) in its capacity as agent for Lenders (as defined below) (the “Agent”), the
Lenders identified on the signature pages hereto (each a “Lender” and collectively, the “Lenders”), and ENDOCYTE, INC., a Delaware corporation (“Borrower”). 

1. DESCRIPTION OF EXISTING INDEBTEDNESS AND OBLIGATIONS. Among other indebtedness and obligations which may be owing by Borrower to the Lenders,
Borrower is indebted to the Lenders pursuant to a loan arrangement dated as of August 27, 2010, evidenced by, among other documents, a certain Loan and Security Agreement dated as of August 27, 2010, and a certain Consent and First Loan
Modification Agreement dated as of December 14, 2010, each among Borrower, Agent and the Lenders (the “Loan Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in
the Loan Agreement. 
 2. DESCRIPTION OF COLLATERAL. Repayment of the Obligations is secured by the Collateral as described in the Loan
Agreement (together with any other document pursuant to which collateral security is granted to Agent for the ratable benefit of the Lenders, the “Security Documents”). Hereinafter, the Security Documents, together with all other
documents evidencing or securing the Obligations shall be referred to as the “Existing Loan Documents”. 
 3. DESCRIPTION OF
CHANGE IN TERMS. 
 Modifications to Loan Agreement. 

 

	 	1.	The Loan Agreement shall be amended by deleting the following text appearing as Section 7.7 thereof: 

“Investments. No Loan Party shall, and no Loan Party shall permit any of its Subsidiaries to, directly or indirectly
(a) acquire or own, or make any loan, advance, capital contribution, “earnout” payment or similar payment in respect to any acquisition of assets or stock of any person (an “Investment”) in or to any person or entity
(other than to another Loan Party to the extent permitted under the terms and conditions set forth in Section 7.2(e), (b) acquire or create any Subsidiary, or (c) engage in any joint venture or partnership with any other person or
entity (excluding any Equity Financing Event), other than: (i) Investments existing on the date hereof and set forth in the Perfection Certificate, (ii) Investments in cash and Cash Equivalents (as defined below), and other Investments
permitted by Borrower’s investment policy that has been approved in writing by Agent from time to time, (iii) loans or advances to employees of Borrower or any of its Subsidiaries to finance travel, entertainment and relocation expenses
and other ordinary business purposes in the ordinary course of business and loans in the nature of signing bonuses, provided that the aggregate outstanding principal amount of all loans and advances permitted

 
pursuant to this clause (iii) shall not exceed $150,000 at any time (collectively, the “Permitted Investments”), (iv) Investments (including debt obligations) received
in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business, (v) Investments consisting
of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business, (vi) Investments consisting of loans to employees, officers or directors relating
to the purchase of equity securities of Borrower pursuant to employee stock purchase plan agreements approved by Borrower’s Board of Directors that do not result in disbursements of cash by the Borrower and the other Loan Parties, and
(vii) other Investments in an aggregate amount not to exceed $250,000 (collectively, the “Permitted Investments”). The term “Cash Equivalents” means (v) any readily-marketable securities (i) issued
by, or directly, unconditionally and fully guaranteed or insured by the United States federal government or (ii) issued by any agency of the United States federal government the obligations of which are fully backed by the full faith and credit
of the United States federal government, (w) any readily-marketable direct obligations issued by any other agency of the United States federal government, any state of the United States or any political subdivision of any such state or any
public instrumentality thereof, in each case having a rating of at least “A-1” from S&P or at least “P-1” from Moody’s, (x) any commercial paper rated at least “A-l” by S&P or
“P-1” by Moody’s and issued by any entity organized under the laws of any state of the United States, (y) any U.S. dollar-denominated time deposit, insured certificate of deposit, overnight bank deposit or bankers’
acceptance issued or accepted by (i) Agent or (ii) any commercial bank that is (A) organized under the laws of the United States, any state thereof or the District of Columbia, (B) “adequately capitalized” (as defined in the
regulations of its primary federal banking regulators) and (C) has Tier 1 capital (as defined in such regulations) in excess of $250,000,000 or (z) shares of any United States money market fund that (i) has substantially all of its
assets invested continuously in the types of investments referred to in clause (v), (w), (x) or (y) above with maturities as set forth in the proviso below, (ii) has net assets in excess of $500,000,000 and
(iii) has obtained from either S&P or Moody’s the highest rating obtainable for money market funds in the United States; provided, however, that the maturities of all obligations specified in any of clauses (v),
(w), (x) and (y) above shall not exceed 365 days. 

  
 -2-

 and inserting in lieu thereof the following: 

“Investments. No Loan Party shall, and no Loan Party shall permit any of its Subsidiaries to, directly or indirectly
(a) acquire or own, or make any loan, advance, capital contribution, “earnout” payment or similar payment in respect to any acquisition of assets or stock of any person (an “Investment”) in or to any person or entity
(other than to another Loan Party to the extent permitted under the terms and conditions set forth in Section 7.2(e), (b) acquire or create any Subsidiary, or (c) engage in any joint venture or partnership with any other person or
entity (excluding any Equity Financing Event), other than: (i) Investments existing on the date hereof and set forth in the Perfection Certificate, (ii) Investments in cash and Cash Equivalents (as defined below), and other Investments
permitted by Borrower’s investment policy that has been approved in writing by Agent from time to time, (iii) loans or advances to employees of Borrower or any of its Subsidiaries to finance travel, entertainment and relocation expenses
and other ordinary business purposes in the ordinary course of business and loans in the nature of signing bonuses, provided that the aggregate outstanding principal amount of all loans and advances permitted pursuant to this clause (iii) shall
not exceed $150,000 at any time, (iv) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with,
customers or suppliers arising in the ordinary course of business, (v) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of
business, (vi) Investments consisting of loans to employees, officers or directors relating to the purchase of equity securities of Borrower pursuant to employee stock purchase plan agreements approved by Borrower’s Board of Directors that
do not result in disbursements of cash by the Borrower and the other Loan Parties, (vii) Investments consisting of capital contributions and/or loans to a wholly-owned Subsidiary of Borrower organized under the laws of the Netherlands
(“EU Holdco”), in an aggregate amount not to exceed $2,000,000, and (viii) other Investments in an aggregate amount not to exceed $250,000 (collectively, the “Permitted Investments”). The term “Cash
Equivalents” means (v) any readily-marketable securities (i) issued by, or directly, unconditionally and fully guaranteed or insured by the United States federal government or (ii) issued by any agency of the United States
federal government the obligations of which are fully backed by the full faith and credit of the United States federal government, (w) any readily-marketable direct obligations issued by any other agency of the United States federal government,
any state of the United States or any political subdivision of any such state or any public instrumentality thereof, in each case having a rating of at least “A-1” from S&P or at least “P-1” from Moody’s, (x) any

  
 -3-

 
commercial paper rated at least “A-1” by S&P or “P-1” by Moody’s and issued by any entity organized under the laws of any state of the United States,
(y) any U.S. dollar-denominated time deposit, insured certificate of deposit overnight bank deposit or bankers’ acceptance issued or accepted by (i) Agent or (ii) any commercial bank that is (A) organized under the laws of
the United States, any state thereof or the District of Columbia, (B) “adequately capitalized” (as defined in the regulations of its primary federal banking regulators) and (C) has Tier 1 capital (as defined in such regulations)
in excess of $250,000,000 or (z) shares of any United States money market fund that (i) has substantially all of its assets invested continuously in the types of investments referred to in clause (v), (w), (x) or
(y) above with maturities as set forth in the proviso below, (ii) has net assets in excess of $500,000,000 and (iii) has obtained from either S&P or Moody’s the highest rating obtainable for money market funds in the United
States; provided, however, that the maturities of all obligations specified in any of clauses (v), (w), (x) and (y) above shall not exceed 365 days. 

 

	 	2.	The Loan Agreement shall be amended by deleting the following text appearing as the first paragraph of Section 7.10 thereof: 

“Deposit Accounts and Securities Accounts. On and after the date which is thirty (30) days after the Closing Date, each
Loan Party shall maintain all of its and all of its Subsidiaries’ operating and other deposit accounts and securities accounts with SVB and/or SVB’s Affiliates; provided, that (i) Borrower may maintain a petty cash account (#135380)
with Lafayette Bank and Trust (“Lafayette Bank”) in Lafayette, Indiana (the “Lafayette Account”) provided that the aggregate amount on deposit in the Lafayette Account shall not exceed $10,000 at any time (other
than in connection with the receipt into such account of payments of up to $5,000,000 in connection with the Therapeutic Discovery Project Credit program, provided that Borrower shall cause such monies to be transferred to an account maintained by
Borrower with SVB or an Affiliate of SVB that is subject to an Account Control Agreement within three (3) Business Days of receipt thereof), (ii) Borrower may maintain a certificate of deposit (account #61058044) with Lafayette Bank (the
“Lafayette Cash Collateral Account”) as cash collateral for the benefit of Lafayette Bank, provided, that (a) the aggregate principal balance of such certificate of deposit shall not exceed $500,000 at any time, (b) the
aggregate amount of indebtedness which is secured by amounts on deposit in the Lafayette Cash Collateral Account shall not at any time exceed $19,000, and (c) Borrower shall cause all monies on deposit or invested in the Lafayette Cash
Collateral Account to be transferred to an account maintained by Borrower with SVB or an Affiliate of SVB that is subject to an Account Control Agreement within 

  
 -4-

 
three (3) Business Days of payment in full the indebtedness secured by such monies, and (iii) Borrower may maintain account #9000088096 with Lafayette Bank and account #61058044 with
First Merchants Trust provided that such accounts are closed on or prior to the date which is thirty (30) days after the Closing Date and all assets therein are transferred to an account maintained by Borrower with SVB or an Affiliate of SVB
that is subject to an Account Control Agreement. 
 and inserting in lieu thereof the following: 

“Deposit Accounts and Securities Accounts. On and after the date which is thirty (30) days after the Closing Date, each
Loan Party shall maintain all of its and all of its Subsidiaries’ operating and other deposit accounts and securities accounts with SVB and/or SVB’s Affiliates; provided, that (i) Borrower may maintain a petty cash account (#135380)
with Lafayette Bank and Trust (“Lafayette Bank”) in Lafayette, Indiana (the “Lafayette Account”) provided that the aggregate amount on deposit in the Lafayette Account shall not exceed $10,000 at any time (other
than in connection with the receipt into such account of payments of up to $5,000,000 in connection with the Therapeutic Discovery Project Credit program, provided that Borrower shall cause such monies to be transferred to an account maintained by
Borrower with SVB or an Affiliate of SVB that is subject to an Account Control Agreement within three (3) Business Days of receipt thereof), (ii) Borrower may maintain a certificate of deposit (account #61058044) with Lafayette Bank (the
“Lafayette Cash Collateral Account”) as cash collateral for the benefit of Lafayette Bank, provided, that (a) the aggregate principal balance of such certificate of deposit shall not exceed $500,000 at any time, (b) the
aggregate amount of indebtedness which is secured by amounts on deposit in the Lafayette Cash Collateral Account shall not at any time exceed $19,000, and (c) Borrower shall cause all monies on deposit or invested in the Lafayette Cash
Collateral Account to be transferred to an account maintained by Borrower with SVB or an Affiliate of SVB that is subject to an Account Control Agreement within three (3) Business Days of payment in full the indebtedness secured by such monies,
(iii) Borrower may maintain account #9000088096 with Lafayette Bank and account #61058044 with First Merchants Trust provided that such accounts are closed on or prior to the date which is thirty (30) days after the Closing Date and all
assets therein are transferred to an account maintained by Borrower with SVB or an Affiliate of SVB that is subject to an Account Control Agreement and (iv) EU Holdco may maintain accounts with ABN Amro, provided that the aggregate principal
balances of such accounts shall not at any time exceed $2,000,000 (or the € EURO equivalent), less all operating expenses paid by EU Holdco on and after July 19, 2011. 

  
 -5-

 4. EXPENSES. Borrower shall reimburse Agent and the Lenders for all legal fees and out-of pocket
expenses incurred in connection with this Loan Modification Agreement. 
 5. RATIFICATION OF LOAN DOCUMENTS. Borrower hereby ratifies,
confirms, and reaffirms all terms and conditions of all security or other collateral granted to Agent for the ratable benefit of the Lenders, and confirms that the indebtedness secured thereby includes, without limitation, the Obligations.

 6. PERFECTION CERTIFICATE. Borrower hereby ratifies, confirms and reaffirms, all and singular, the terms and disclosures contained in
Borrower’s Perfection Certificate dated as of July 19, 2011, and acknowledges, confirms and agrees the disclosures and information Borrower provided to Agent and the Lenders in such Perfection Certificate have not changed, as of the date
hereof. 
 7. NO DEFENSES OF BORROWER. Borrower hereby acknowledges and agrees that Borrower has no offsets, defenses, claims, or
counterclaims against Agent and/or the Lenders with respect to the Obligations, or otherwise, and that if Borrower now has, or ever did have, any offsets, defenses, claims, or counterclaims against Agent and/or the Lenders, whether known or unknown,
at law or in equity, all of them are hereby expressly WAIVED and Borrower hereby RELEASES Agent and/or the Lenders from any liability thereunder. 
 8. REPRESENTATIONS AND WARRANTIES. To induce Agent and Lenders to enter into this Loan Modification Agreement Borrower does hereby warrant, represent and covenant to Agent and Lenders that after
giving effect to this Loan Modification Agreement (i) each representation or warranty of Borrower set forth in the Loan Agreement is hereby restated and reaffirmed as true and correct in all material respects on and as of the date of this Loan
Modification Agreement as if such representation or warranty were made on and as of the date of this Loan Modification Agreement (except to the extent that any such representation or warranty expressly relates to a prior specific date or period),
(ii) no Default or Event of Default has occurred and is continuing as of the date hereof and (iii) Borrower has the power and is duly authorized to enter into, deliver and perform this Loan Modification Agreement and this Loan Modification
Agreement is the legal, valid and binding obligation of Borrower enforceable against Borrower in accordance with its terms. 
 9. CONTINUING
VALIDITY. Except as expressly modified pursuant to this Loan Modification Agreement, the terms of the Existing Loan Documents remain unchanged and in full force and effect. The Lenders’ agreement to modifications to the existing Obligations
pursuant to this Loan Modification Agreement in no way shall obligate Agent or the Lenders to make any future modifications to the Obligations. Nothing in this Loan Modification Agreement shall constitute a satisfaction of the Obligations. It is the
intention of Agent, the Lenders and Borrower to retain as liable parties all makers of Existing Loan Documents, unless the party is expressly released by the Lenders in writing. No maker will be released by virtue of this Loan Modification
Agreement. 
 10. CONDITION PRECEDENT TO EFFECTIVENESS OF THIS LOAN MODIFICATION AGREEMENT. This Loan Modification Agreement shall become
effective as of date referred to above upon the receipt by Agent, in form and substance satisfactory to Agent and Lenders, of one or more counterparts of this Loan Modification Agreement duly executed and delivered by the Borrower, Agent and
Lenders. 
 11. POST CLOSING COVENANT. On or before the date that is two (2) Business Days after the formation of EU Holdco,
Borrower shall deliver to Agent and the Lenders a completed perfection 

  
 -6-

 
certificate in the form Agent previously delivered to Borrower duly executed by EU Holdco. Failure of Borrower to timely deliver such Perfection Certificate shall constitute an Event of Default
under the Loan Agreement. 
 12. COUNTERPARTS. This Loan Modification Agreement may be executed in multiple counterparts, each of which
shall be deemed to be an original and all of which when taken together shall constitute one and the same instrument. 
 13. GOVERNING
LAW. THIS LOAN MODIFICATION AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF MARYLAND APPLICABLE TO CONTRACTS MADE AND PERFORMED IN SUCH STATE WITHOUT REGARD TO THE PRINCIPLES THEREOF REGARDING
CONFLICTS OF LAWS. 
 14. ENTIRE AGREEMENT. The Existing Loan Documents as and when amended through this Loan Modification Agreement
embody the entire agreement between the parties hereto relating to the subject matter thereof and supersede all prior agreements, representations and understandings, if any, relating to the subject matter thereof. 

[Remainder of Page Intentionally Left Blank – 
 Signature Page(s) to Follow.] 

  
 -7-

 IN WITNESS WHEREOF, the parties hereto have caused this Loan Modification Agreement to be
executed as of the date first written above. 
  

			
	BORROWER:
	
	ENDOCYTE, INC.
		
	By	 	 /s/ Michael Sherman

	Name:	 	 MICHAEL SHERMAN

	Title:	 	 CFO

	
	LENDERS:
	
	MIDCAP FUNDING V, LLC, as Agent and as a Lender
		
	By	 	  

	Name:	 	  

	Title:	 	  

	
	SILICON VALLEY BANK, as a Lender
		
	By	 	  

	Name:	 	  

	Title:Letter Agreement

 Exhibit 10.1 
 

 
 June 24,2011 
 VIA E-Mail & U. S. Mail 
 Andrew C. Johannesen 

Dear Andrew: 
 I am pleased to offer you the
position of Senior Vice President-Finance and Treasurer based in our Houston office located at 2105 City West Blvd., Suite 500, Houston, TX 77042. The anticipated start date for your position is to be mutually determined. 

 

	 	1.	Salary. $10,416.66 per semi-monthly pay period ($250,000 per year). 

 

	 	2.	Signing Bonus. You will receive a signing bonus of $35,000 upon commencement of your first day of employment. 

 

	 	3.	Stock Award. You will receive a restricted stock award with a face value of $200,000 under the Company’s 2006 Incentive Plan. The number of shares of Omega
Protein common stock will be equal to 200,000 divided by the average of the Company’s common stock high and low trading prices on the NYSE on your first day of employment with the Company. The stock award will vest 100% on the third anniversary
of your date of employment, and will be subject to the restrictions set forth in the Award and the 2006 lncentive Plan. Upon a Change of Control (as defined in the 2006 lncentive Plan) of the Company, all restrictions and conditions on the Award
will be deemed satisfied and the vesting period will be deemed to have expired. 

  

	 	4.	Year-End Bonus. Commencing in 2011, you will be eligible to receive a year- end cash bonus to be determined by the Company. 

 

	 	5.	Benefits. All benefits will be in accordance with Company policies, plans and procedures including but not limited to: 

 

	 	A.	Health insurance under the Company’s health care plan. 

  

	 	B.	Dental insurance under the Company’s health care plan. 

  

	 	C.	Life insurance contingent upon your enrollment in the health insurance benefit program. 

 

	 	D.	Disability insurance under the Company insurance program. 

 2105 City West Boulevard, Suite 500 • Houston, Texas 77042-2838 • Telephone (713) 623-0060 • Fax (713) 940-6122 

	 	E.	Participation in the Company’s 401 (k) Plan, with the benefit of a Company matching contribution. 

 

	 	F.	Vacation of 4 weeks per year. 

  

	 	6.	Drug Test and Background Check. This offer is conditioned on your passing a routine drug test and in accordance with Company policy and the Company’s
satisfactory review of a background check on you. 

  

	 	7.	Employee Confidentiality, Assignment of lnventions and Non-compete Agreement. Enclosed is a copy of the Omega Protein Employee Confidentiality, Assignment of
lnventions and Non-compete Agreement. The offer is also conditional on our mutual execution of this Agreement. 

 Any other
benefits are covered in the Omega Employee Handbook and/or Administrative Manual and are subject to Company policy. 
 As you know, this letter
does not serve as an employment contract. Employment is for no fixed duration and may be terminated by either party at any time for any reason. 

By executing and returning this letter, you are also confirming that you are not subject to any non-competition agreement, non-solicitation agreement or
other restrictive covenant from your current employer or any other party. 
 If you agree with the terms and conditions of this offer and
confirm the above paragraph, I would appreciate your signing the enclosed copy of the letter in the space below and returning it to me by email or by fax at 713-940-6122. 

	
	Sincerely,
	
	/s/ Bret Scholtes
	Bret Scholtes

 AGREED and ACCEPTED: 
  

					
			
	 /s/ Andrew Johannesen
	 	Date:	 	6/24/11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}]]